BB BIOTECH AG

BION
Delayed Quote. Delayed  - 12/02 11:30:36 am
76.85CHF -3.88%

BB Biotech : Interim report as at June 30, 2021

07/23/2021 | 01:18am

The corona pandemic continues to hold the world in its grip. The biotech industry, on the other hand, is additionally moved by a new drug, the Alzheimer's drug Aduhelm from Biogen. A few weeks ago, this drug received FDA approval in June of this year. Find out more in a conversation with Dr. Daniel Koller, Head Investment Team, on the occasion of the half-year figures of BB Biotech AG 2021.

Disclaimer

BB Biotech AG published this content on 23 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 23 July 2021 05:17:09 UTC.

© Publicnow 2021
Copier lien
All news about BB BIOTECH AG
10/22
10/22
10/22
10/22
10/22